Impax Laboratories Inc. agreed to pay $20 million to consumers and insurers to resolve claims in an antitrust lawsuit related to Valeant Pharmaceuticals International Inc.'s acne medication Solodyn, Reuters reported.

The lawsuit, a portion of which was settled by the Hayward, Calif.-based pharmaceutical company earlier this month, alleged that Impax was involved in a pay-for-delay deal which kept cheaper versions of Solodyn from entering the market.

The accord was disclosed in papers filed in federal court in Boston, the news outlet added.